Kineta provides new data on VISTA biomarker and KVA12123 Phase 1/2 data

Kineta announced the presentation of new VISTA biomarker data and an update on the KVA12123 Phase 1/2 clinical trial at the American Association for Cancer Research Annual Meeting 2023. Key results from the AACR poster presentation: VISTA expression was detected by immunohistochemistry on tumor infiltrating immune cells, especially in non-small cell lung cancer, colorectal cancer, ovarian cancer, cervical cancers, melanoma and hepatocellular carcinomas and VISTA expression was also detected on rare tumor cells in lung, head and neck, ovary and kidney malignancies; multiplex IHC will be performed to confirm VISTA-positive tumor-infiltrating myeloid cells; high levels of soluble VISTA were found in colorectal, head & neck, kidney, lung and ovarian cancer patient serum samples; in the ongoing Phase 1/2 clinical trial, tumor tissues and serum samples will be collected from cancer patients prior to treatment with KVA12123 to inform the possible significance of these biomarkers. This work will help to better understand the clinical response to KVA12123 in relation to the expression level of VISTA in cancer tissues as well as in the blood and opens the possibility to consider VISTA expression as a potential biomarker for efficacy.